Trial Profile
Phase I Study To Establish Maximum Tolerated Dose (MTD) of Cyberknife in Patients With Un-Resectable Pancreas Cancer (TL002)
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 31 Jul 2019
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- 26 Jul 2019 Status changed from recruiting to discontinued.
- 11 Dec 2018 New trial record